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women	hereafter	 because	most	 the	majority	 of	 people	who	 seek	 to	
access	abortion	services	 identify	as	women),	 to	do	so	 they	must	put	
themselves	and,	by	extension,	those	they	live	with,	at	risk	of	COVID‐19	
infection.	 In	many	 cases	 these	obstacles	were	pre‐existing	 and	have	
simply	been	exacerbated,	whereas	others	have	only	recently	arisen.
Abortion	 care	 is	 necessary	 to	 aid	 women	 seeking	 respite	 from	
unwanted	and/or	unsafe	pregnancy,2	which	has	a	 significant	 impact	
on	 physical	 and	mental	 health.3	 It	 is	 also	 necessary	 to	mitigate	 the	
impact	of	unsafe	abortion.4	Consequently,	abortion	care	is	recognized	
as	a	human	rights	imperative—to	protect	the	lives,	bodily	autonomy,	
and	 reproductive	 autonomy	 of	 women.2,3	 Sexual	 and	 reproductive	
health	 care	 remains	 crucial	 during	 the	 pandemic.	 Some	 have	 noted	




[Maternal	 and	 Newborn	 Health]	 Services	 will	 result	 in	 many	 thou‐
sands	of	maternal	and	newborn	deaths	due	to	millions	of	additional	
unintended	pregnancies,	unsafe	abortions	and	complicated	deliveries	
without	 access	 to	 essential	 and	 emergency	 care’.6	Despite	 abortion	
care being necessary to ensure the health and safety of many women, 
the	pandemic	has	exacerbated	existing	disparities	in	access	that	exist	
in many countries globally. In some instances, this is the direct result 
of	existing	or	newly	implemented	legal	and	policy	barriers	to	care.	In	
this	paper	we	consider	some	of	the	ways	in	which	abortion	care	might	
be	 appropriately	 facilitated	 in	 pandemic	 circumstances	 by	 providers	
adapting,	 for	 example	 by	 providing	 early	 medical	 abortion	 (EMA)	
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
©	2020	The	Authors.	International Journal of Gynecology & Obstetrics	published	by	John	Wiley	&	Sons	Ltd	on	behalf	of	International	Federation	of	Gynecology	and	
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through	 telemedical	 services	 (TEMA).	 The	 terms	 ‘telemedicine’	 and	




















EMA	 is	 the	use	of	 two	drugs—mifepristone	 and	misoprostol—taken	
24–48	hours	apart	to	procure	an	abortion.	This	drug	regimen,	how‐
ever,	is	not	universally	approved.	Mifepristone	was	first	approved	for	






ability	 of	 the	 procedure	 are	 well	 established.	 As	 such,	 it	 is	 recom‐
mended	by	the	WHO	for	use	up	to	nine	weeks	of	gestation.10	Different	
jurisdictions	have	slightly	different	gestational	limits,	though	they	are	
generally	 around	 the	 10‐week	mark.	 EMA	 has	 been	 praised	 for	 its	
ability	 to	 enable	 self‐managed	 abortion,	 and	 to	 drastically	 decrease	
maternal	morbidity	and	mortality—particularly	in	the	global	south.11
TEMA	is	the	use	of	telemedical	means	to	provide	EMA	remotely.	
TEMA	 has	 been	 in	 practice	 in	 some	 countries	 for	 over	 a	 decade.	
However,	 there	 is	 substantial	 variation	 in	 the	models	 adopted,	 and	
what	is	generally	thought	of	as	TEMA	today—a	consultation	by	tele‐
phone	or	video	call	before	abortifacients	are	posted	 to	 the	 service‐
user—is	a	more	recent	development.	Whilst	there	are	small	differences	
between	 each	TEMA	 service,	 there	 are	 some	 common	models	 that	
have	developed.









By	 removing	 all	 in‐person	 requirements,	 the	 services	 offered	
globally	 by	 transnational	 abortion	providers	 further	 improve	 access.	
Following	 the	 completion	 of	 an	 online	 questionnaire‐based	 con‐
sultation,	 abortifacients	 are	 posted	 to	women	 as	 appropriate.	 Such	
services,	however,	 are	 still	 limited	 in	 their	 reach	 for	 reasons	we	will	
explain	later	in	this	paper.
More	 recently—and	 in	 response	 to	 the	 pandemic—the	 British	
Pregnancy	Advisory	Service	 (BPAS—the	 leading	provider	of	abortion	
services	 in	 England	 and	Wales)	 introduced	what	 can	 be	 considered	
a	 middle	 ground	 model	 between	 those	 already	 outlined.	 Women	
undergo	 a	 telephone	 consultation	 and,	 assuming	 doctor	 approval,	
are	 posted	 a	 pack	 including	 the	necessary	 drugs	 and	 information.12 
This,	we	argue,	 is	 a	preferable	model	 as	 it	 combines	 the	ease	of	an	
entirely	remote	service	with	the	safeguards	of	a	full,	live	consultation.	
However,	we	acknowledge	that	a	variety	of	models	will	be	necessary	
to meet the needs of individual countries. In areas where women may 
not	 have	 access	 to	 an	 internet	 connection	 or	 private	 telephone,	 a	
system	involving	the	collaboration	of	local	healthcare	facilities	which	
are	 not	 authorized	 to	 prescribe	 abortifacients	 themselves	 may	 be	
more	appropriate.
3  | ABORTION CARE DURING COVID‐19
3.1 | Practical barriers to in‐person abortion care
Those	 seeking	 to	 access	 abortion	 services	 frequently	 face	 practical	
barriers.	 Perhaps	 the	 most	 common,	 and	 one	which	 is	 fed	 into	 by	
many	others,	is	the	distance	to	the	nearest	clinic.	So‐called	“abortion	




a	private	vehicle.	 In	 that	 sense,	 socioeconomic	 status	 can	challenge	




permitted,	 though	 some	 countries	 have	been	 slow	 to	 allow	 this,	 let	
alone	TEMA.13	These	medications	can	act	very	quickly,	meaning	that	
where	the	taking	of	medication	is	required	to	be	supervised	there	is	a	
risk of the induced miscarriage beginning on the journey home, such 
that living far from a clinic increases the likelihood of this.
Having	 to	 attend	 a	 clinic	 in	 person	may	 also	 be	 challenging	 for	
those	who	work	 full‐time,	have	children,	and/or	care	 for	other	 rela‐
tives.5	This	is	the	case	regardless	of	the	distance	to	the	nearest	clinic.	
Taking	time	off	work	 and	 arranging	 alternative	 care	 for	 dependents	
may	not	be	immediately	feasible.	For	women	who,	for	whatever	rea‐
son,	 do	 not	want	 others	 to	 know	 that	 they	 are	 having	 an	 abortion,	
this	may	be	even	more	difficult.	Whereas	a	manager,	for	example,	may	
be	 sympathetic	 and	 allow	 an	 employee	 time	 off	work	 to	 attend	 an	
     |  3Romanis and PaRsons
abortion	clinic,	this	would	require	that	employee	to	share	this	personal	






The	 above	 issues	 are	 longstanding.	 However,	 the	 COVID‐19	 pan‐
demic	has	exacerbated	them,	thereby	amplifying	the	case	for	TEMA.	
Whereas	responses	to	the	pandemic	vary	between	countries,	the	vast	
majority have introduced some form of social distancing or lockdown. 
These	measures	make	it	more	challenging	for	those	seeking	abortion	
services	to	get	to	a	clinic	even	if	they	live	within	close	proximity.	With	
schools	 closed,	 caring	 responsibilities	 have	 increased	 for	 parents.	
Having	to	manage	childcare	along	with,	 in	some	cases,	 the	move	to	
at‐home	working,	can	make	it	difficult	to	leave	the	house	alone.	Even	
for	 those	who	 can,	 and	 those	who	do	not	 have	 caring	 responsibili‐
ties	there	has	been,	and	in	many	cases,	there	remains,	an	expectation	





struggle to get to work or may even fall ill themselves at a greater 
rate	 than	 prevails	 in	 their	 community.	 Marie	 Stopes	 International	
have	noted	that	‘both	support	and	frontline	staff	have	been	unable	to	
work,	due	 to	movement	 restrictions,	 illness	 [and]	 family	demands’.14 
The	impact	of	this	in	some	places	could	(and	has)	force(d)	some	clinics	
to	close	 temporarily.	Where	 this	happens,	 the	distance	 to	 the	near‐
est	 clinic	would	 increase	 for	 some	 patients.	 In	 Great	 Britain,	 BPAS	
announced in March 2020 that 23% of its clinics had closed because 
of	the	pandemic.15	There	are	concerns	about	the	health	and	safety	of	
both	staff	and	service	users	where	clinics	stay	open.
All	 these	obstacles	 risk	preventing,	or	at	 the	very	 least	delaying,	
access	 to	essential	abortion	services.	This	 is	problematic	due	to	 the	
time‐sensitive	 nature	 of	 abortion,	 both	medically	 and	 legally/politi‐
cally.	We	know	that	even	 though	EMA	 is	 feasible	past	12	weeks	of	
gestation,10	the	risk	of	incomplete	abortion	and	various	other	compli‐
cations	increases	with	time.	If	a	pregnancy	is	going	to	be	terminated,	
the	earlier	this	 is	done	the	safer	it	 is.	Furthermore,	 in	some	places	it	
is	 far	more	 difficult	 to	 find	 clinics	 that	 provide	 later‐term	 abortions	
even where this is legal.16	The	 legal	 obstacle	 also	 increases	 later	 in	









as a result of, among other reasons, limits on the mobility of those 
seeking care.17
Failure	to	ensure	service	provision	has	a	‘disparate	impact	on	those	
with low or no incomes and or who lack housing, migrants, refugees, 




people	who	are	 already	 structurally	disadvantaged,	 have	 a	disability	











3.3 | TEMA and other solutions
TEMA	 is	one	 important	way	 to	 facilitate	 continued	access	 to	 abor‐




long)	 distances	 and	 increasing	 their	 exposure	 to	 COVID‐19.	 It	 also	








Whilst	 TEMA	 can	 address	 some	 of	 the	 barriers	 to	 care	 at	 this	
time	 from	 the	perspective	of	 the	woman	accessing	 care,	 there	may	
be	some	difficulty	experienced	by	providers	where	 legal	 restrictions	
prevent	 task‐sharing	 in	abortion	care.	Even	 though	 there	 is	 increas‐
ing	 evidence	 that	 nurses	 and	 other	 healthcare	 providers	 can	 safely	
prescribe	abortifacients,19	in	many	jurisdictions	the	law	dictates	that	
only	 doctors	 can	 prescribe	 the	 medications,	 for	 example	 in	 Great	
Britain.20	This	raises	some	problems	for	providers	in	that	it	limits	the	
provider	pool	and	 increases	both	waiting	times	and	the	cost	of	pro‐
viding care.19	The	WHO	 recommends	 that	 task‐sharing	 be	 adopted	
in	the	delivery	of	health	services	to	optimize	delivery.21,22 During the 
pandemic	 (and	 beyond),	 permitting,	 for	 example,	 nurse	 prescribing	
would	simplify	access	and	reduce	administrative	burdens	on	doctors,	
thereby enabling doctors to focus on cases that involve more com‐
plex	management.	There	 is	some	extent	to	which	regional	providers	
have	already	attempted	to	adopt	task‐sharing	as	far	as	is	possible—for	
4  |     Romanis and PaRsons











no	 touch’	 treatment.24	 Without	 performing	 physical	 examinations	
and/or	ultrasounds,	providers	can	still	reduce	the	risk	of	transmission	
between	themselves	and	patients.
4  | LEGAL AND POLICY CONTEXT OF 
ABORTION CARE DURING COVID‐19




forms	 and,	 in	many	 cases,	 restrictions	 on	 service	 provision	were	 in	
place	before	the	pandemic.	This	meant	that	to	address	access	issues	




being and access to care.
First,	 in	 some	 countries	 there	 are	 explicit	 bans	on	 the	provision	






tions	 in	 Northern	 Ireland	 prior	 to	 the	 decriminalisation	 of	 abortion	
in	2019).25	 In	Spain,	action	has	been	taken	to	block	the	websites	of	
these	providers.26,27
Second,	 in	 some	 countries	 there	 are	 other	 restrictions	 which,	
whilst	 not	 an	 explicit	 ban	 on	TEMA	or	 remote	 care	 itself,	 have	 the	
effect	 of	 rendering	 it	 inaccessible	 because	 other	 legal	 requirements	





Nebraska,	 Oklahoma,	 South	 Dakota,	 and	 Texas).5	 Other	 procedural	
requirements	 embedded	 in	 abortion	 law	 in	 some	countries,	 such	 as	
mandatory	 counselling	 or	 ‘reflection	 delays’,28 might not necessar‐
ily	 preclude	 remote	 care,	 but	 still	 constitute	 a	 significant	 barrier	 to	










must	 take	place	under	 the	 service	of	obstetrics	 and	gynaecology	 in	




and	Public	Health.30 In Ghana, the Criminal Code similarly states that 






means	of	 transport	 to	hospital.32	Similar	 laws	are	 in	place	 in	several	



















Todd‐Gher	 and	 Shah	 argue	 that	 states	 should	 ‘introduce	 bold,	
innovative	measures	to	maintain	and	expand	access	[to	abortion	care]	
in	accordance	with	human	rights’.3	The	Center	for	Reproductive	Rights	
has	 also	 called	 for	 the	 implementation	of	 telemedicine	 in	 reproduc‐
tive	 health	 services	 to	 ensure	 that’women	 and	 girls	 are	 not	 unnec‐
essarily	 compelled	 to	 make	 multiple	 trips	 to	 healthcare	 facilities’.34 
Further,	 in	 its	 COVID‐19	 guidance	 on	 maintaining	 essential	 health	
services,	 the	WHO	has	recommended	enabling	safe	abortion	to	the	
full	 extent	 of	 the	 law	 and	 to	 ‘minimize	 facility	visits	 and	 provider–‐
client contacts through the use of telemedicine	[emphasis	added]	and	


















service	 providers	 to	 offer	 remote	 consultation	 and	 temporarily	
increased	 the	 gestational	 limit	 for	 self‐administration	 at	 home	 from	
seven to nine weeks.38	In	South	Africa,	telemedicine	had	been	previ‐
ously	used	in	abortion	follow‐up	care,39 but the law on telemedicine 
technically	requires	that	there	be	a	pre‐existing	relationship	between	
patient	 and	 professional.	 However,	 following	 successful	 campaign‐
ing	 by	 the	 Sexual	 and	Reproductive	Justice	Coalition,	Marie	 Stopes	
International	 have	 been	 enabled	 to	 offer	 TEMA	 during	 the	 pan‐
demic.40	Telemedicine	has	also	now	been	permitted	for	pre‐abortion	
counselling	in	Germany	(provided	by	an	independent	third	party	as	per	
the	 requirements	 of	 the	German	Criminal	 Code),	which	 is	 a	 step	 in	
the	 right	 direction,	 despite	 the	 fact	 that	 abortion	 care	must	 still	 be	
administered in a clinic.27	There	have	also	been	some	successful	legal	
challenges	to	policies	that	prevent	access	at	this	time.	For	example,	in	
Maryland	 in	 the	US,	 the	FDA	requirement	 that	mifepristone	be	dis‐
pensed	in	person	was	recently	successfully	challenged,	and	an	injunc‐
tion	 is	 in	 place	 (at	 the	time	of	writing)	 that	 prevents	 the	FDA	 from	









‘divert	resources	to	the	front	line’.42 Rebouché argues that it is more 
likely	that	restricting	abortion	access	will	result	in	greater	strain	on	the	
health	 system	because	 the	alternative	 to	TEMA,	or	 ‘no‐touch	 [early	
medical]	termination’	because	more	people	will	need	assistance	after	
inducing	their	own	abortions,	and	advanced	pregnancy,	childbirth	and	
neonatal care will require more resources.43	This	was	an	attempt	 to	




name.5 In some countries, governments have gone further than label‐
ling	abortion	non‐essential.	In	Slovakia	(where	only	surgical	abortion	





















4.2 | The lasting impact of legal and policy changes 
in response to COVID‐19




might	 find	 accessing	 care	 more	 difficult	 at	 this	 time.	 Furthermore,	
this	 overregulation	 has	 some	wider	 social	 impacts	 and	 perpetuates	
broader	 harms	 to	 women.	 Law	 is	 a	 medium	 through	 which	 stigma	
about	women,	 their	capacities,	and	their	choices	 is	constructed	and	
enforced.46	 The	 requirement	 in	 some	 places	 that	 people	 accessing	
EMA	 are	 ‘supervised’	 swallowing	 mifepristone	 (and	 misoprostol)	 in	
clinics, when this is not grounded in medical necessity,18	perpetuates	
the	view	that	women	are	 irresponsible,	not	 trustworthy,	and/or	are	
incapable	of	making	their	own	decisions	about	abortion.	Being	mind‐








this is not the case. It also increases the likelihood that women will 
access care outside of the health system, which is riskier.
The	progressive	changes	in	countries	like	France,	Great	Britain,	and	
Ireland	must	lead	to	a	permanent	relaxation	of	abortion	restrictions	if	
pregnant	women’s	health	and	 rights	are	 to	be	 respected,	protected,	






service	 provision	 in	 this	 form	 is	 safe,	 effective,	 and	 acceptable	 to	









abide by the highly medicalized model of control entrenched in stat‐
ute’,49	 and	 which	 no	 longer	 reflects	 best	 practice.	 Progressive	 pol‐
icy	 changes	 during	 COVID‐19,	 however,	might	 further	 the	 case	 for	
change	by	demonstrating	their	utility.





In	 these	countries,	 a	disruption	 in	 access,	or	providers	being	 forced	






an	 attempt	 to	 introduce	 even	more	 restrictive	 legislative	 provisions	
restricting	abortion	care	in	April	2020.45	Such	restrictions,	 in	Poland	
and beyond, would threaten the lives and health of millions of women.
5  | CONCLUSION
That	government	responses	to	the	challenges	to	abortion	access	cre‐
ated	 by	 the	 COVID‐19	 pandemic	 are	 so	 varied	 demonstrates	 that	
there	 is	 still	 a	way	 to	 go	until	 abortion	 is	 universally	 recognized	 as	
essential	healthcare.	Even	where	TEMA	has	been	enabled	in	response	
to	COVID‐19,	 it	 is	usually	a	temporary	provision	that	 is	 intended	to	
be	revoked	as	we	emerge	from	the	pandemic.	Whilst	 it	 is	still	posi‐
tive	 that	 such	 provisions	 have	 been	 made,	 it	 is	 important,	 moving	
forward,	 for	 temporary	 policies	 enabling	 remote	 access	 to	 abortion	





























It	 is	essential	 that	access	 to	abortion	 resume	 in	 those	 jurisdictions	
that	 are	 either	 still	 actively	 or	 effectively	 preventing	 abortion	 care	
at	this	time.
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